A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
PT Lukey, SA Harrison, S Yang, Y Man… - European …, 2019 - Eur Respiratory Soc
Phosphatidylinositol 3-kinases (PI3Ks) and mammalian target of rapamycin (mTOR) play a
role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Omipalisib (GSK2126458) is …
role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Omipalisib (GSK2126458) is …
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Rationale Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal of all
fibrotic conditions with no curative therapies. Common pathomechanisms between IPF and …
fibrotic conditions with no curative therapies. Common pathomechanisms between IPF and …
[HTML][HTML] Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
J Wang, K Hu, X Cai, B Yang, Q He, J Wang… - … Pharmaceutica Sinica B, 2022 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic interstitial pneumonia
with unknown causes. The incidence rate increases year by year and the prognosis is poor …
with unknown causes. The incidence rate increases year by year and the prognosis is poor …
CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial
Z Popmihajlov, DJ Sutherland… - BMJ Open …, 2022 - bmjopenrespres.bmj.com
Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal interstitial
lung disease (ILD); other ILDs have a progressive, fibrotic phenotype (PF-ILD). Antifibrotic …
lung disease (ILD); other ILDs have a progressive, fibrotic phenotype (PF-ILD). Antifibrotic …
[HTML][HTML] Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is an advancing and fatal lung disease with increasing
incidence and prevalence. Nintedanib and pirfenidone were approved by the FDA for the …
incidence and prevalence. Nintedanib and pirfenidone were approved by the FDA for the …
Evaluation of pirfenidone and nintedanib in a human lung model of fibrogenesis
KM Roach, E Castells, K Dixon, S Mason… - Frontiers in …, 2021 - frontiersin.org
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with a
poor prognosis and increasing incidence. Pirfenidone and nintedanib are the only approved …
poor prognosis and increasing incidence. Pirfenidone and nintedanib are the only approved …
Use of animal models in IPF research
R Carrington, S Jordan, SC Pitchford… - Pulmonary pharmacology …, 2018 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with a poor prognosis
and limited treatment options. Many compounds have shown efficacy in preclinical models …
and limited treatment options. Many compounds have shown efficacy in preclinical models …
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
M Molina-Molina, C Machahua-Huamani… - BMC pulmonary …, 2018 - Springer
Background Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down
disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung …
disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung …
[HTML][HTML] Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis
L Richeldi, U Costabel, M Selman… - … England Journal of …, 2011 - Mass Medical Soc
Background Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality
rate. Because the signaling pathways activated by several tyrosine kinase receptors have …
rate. Because the signaling pathways activated by several tyrosine kinase receptors have …
The JAK2 pathway is activated in idiopathic pulmonary fibrosis
J Milara, G Hernandez, B Ballester, A Morell, I Roger… - Respiratory …, 2018 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal
fibrotic disorder, with no curative therapies. The signal transducer and activator of …
fibrotic disorder, with no curative therapies. The signal transducer and activator of …